PL3528791T3 - Kompozycje dyspergowalne - Google Patents

Kompozycje dyspergowalne

Info

Publication number
PL3528791T3
PL3528791T3 PL17794275.2T PL17794275T PL3528791T3 PL 3528791 T3 PL3528791 T3 PL 3528791T3 PL 17794275 T PL17794275 T PL 17794275T PL 3528791 T3 PL3528791 T3 PL 3528791T3
Authority
PL
Poland
Prior art keywords
dispersable
compositions
dispersable compositions
Prior art date
Application number
PL17794275.2T
Other languages
English (en)
Polish (pl)
Inventor
Harshad PATANKAR
Nicolaas Martha Felix Goyvaerts
Gopal Rajan RANGA RAJAN
Original Assignee
Janssen Sciences Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Company filed Critical Janssen Sciences Ireland Unlimited Company
Publication of PL3528791T3 publication Critical patent/PL3528791T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
PL17794275.2T 2016-10-24 2017-10-23 Kompozycje dyspergowalne PL3528791T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Publications (1)

Publication Number Publication Date
PL3528791T3 true PL3528791T3 (pl) 2024-04-02

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17794275.2T PL3528791T3 (pl) 2016-10-24 2017-10-23 Kompozycje dyspergowalne

Country Status (21)

Country Link
US (2) US11065198B2 (enExample)
EP (2) EP3528791B1 (enExample)
JP (2) JP7197474B2 (enExample)
KR (2) KR20190073450A (enExample)
CN (1) CN110191704A (enExample)
CA (1) CA3039562A1 (enExample)
DK (1) DK3528791T3 (enExample)
ES (1) ES2970870T3 (enExample)
FI (1) FI3528791T3 (enExample)
HR (1) HRP20240118T1 (enExample)
HU (1) HUE064823T2 (enExample)
LT (1) LT3528791T (enExample)
MA (1) MA46563B1 (enExample)
MX (1) MX2019004767A (enExample)
PL (1) PL3528791T3 (enExample)
PT (1) PT3528791T (enExample)
RS (1) RS65159B1 (enExample)
SI (1) SI3528791T1 (enExample)
SM (1) SMT202400060T1 (enExample)
TW (1) TWI821163B (enExample)
WO (1) WO2018077815A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
PT2040671T (pt) 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Suspensões aquosas de tmc278
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
RU2740903C2 (ru) * 2014-05-16 2021-01-21 Вивус, Инк. Пероральная рассыпающаяся лекарственная форма для введения аванафила и связанные с ней способы получения и применения

Also Published As

Publication number Publication date
CN110191704A (zh) 2019-08-30
MA46563A (fr) 2019-08-28
CA3039562A1 (en) 2018-05-03
TW201828927A (zh) 2018-08-16
MX2019004767A (es) 2019-07-01
WO2018077815A1 (en) 2018-05-03
EP4248947A3 (en) 2023-11-22
HRP20240118T1 (hr) 2024-04-12
ES2970870T3 (es) 2024-05-31
EP3528791A1 (en) 2019-08-28
EP4248947A2 (en) 2023-09-27
JP2020500168A (ja) 2020-01-09
RU2019115672A (ru) 2020-11-24
KR20190073450A (ko) 2019-06-26
HUE064823T2 (hu) 2024-04-28
JP2023011659A (ja) 2023-01-24
RU2019115672A3 (enExample) 2021-01-21
LT3528791T (lt) 2024-05-27
KR102861006B1 (ko) 2025-09-16
SI3528791T1 (sl) 2024-04-30
US11065198B2 (en) 2021-07-20
BR112019007564A2 (pt) 2019-07-02
PT3528791T (pt) 2024-02-19
DK3528791T3 (da) 2024-01-29
US20220008333A1 (en) 2022-01-13
JP7197474B2 (ja) 2022-12-27
US20200069579A1 (en) 2020-03-05
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30
TWI821163B (zh) 2023-11-11
MA46563B1 (fr) 2024-01-31
EP3528791B1 (en) 2023-12-06
RS65159B1 (sr) 2024-02-29
SMT202400060T1 (it) 2024-03-13

Similar Documents

Publication Publication Date Title
EP3722358A4 (en) COMPOSITION
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3697376T3 (da) Sammensætning
EP3493800A4 (en) CANNABIS
DK3361870T3 (da) Fungicidsammensætninger
DK3416996T3 (da) Hærdelig sammensætning
EP3464424A4 (en) PAI-BASED COATING COMPOSITIONS
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3528902T3 (da) Ringegelsammensætning
PT3261437T (pt) Compostos e composições fungicidas
EP3430073A4 (en) COMPOSITION BASED ON A POLYARYLETHERKETONE COMPOSITION
DK4234656T3 (da) Sammensætninger
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
EP3480228A4 (en) COMPOSITION
IT201700065996A1 (it) Transpallet
DK3316857T3 (da) Multifasiske sammensætninger
EP3556804A4 (en) COMPOSITION
DK3528791T3 (da) Dispergible sammensætninger
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION